Identification

Name
Menotropins
Accession Number
DB00032  (BTD00018, BIOD00018)
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Hormones
Description

Menotropins contains follicle stimulating hormone (FSH) and luteinizing hormone (LH) purified from the urine of postmenopausal women. It is used as a fertility medication that is injected either subcutaneously or intramuscularly. It is composed of LH with 2 subunits, alpha = 92 residues, beta = 121 residues and FSH with 2 subunits, alpha = 92 residues, beta=111 residues.

Protein structure
Db00032
Protein chemical formula
C1014H1609N287O294S27
Protein average weight
23390.3 Da
Sequences
>AlphaChain (LH)
APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
>BetaChain (LH)
SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYR
DVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLF
L
>AlphaChain (FSH)
APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
>BetaChain (FSH)
NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYET
VRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
Download FASTA Format
Synonyms
  • Human menopausal gonadotrophin
  • Menotrophin
  • Menotropin
  • Menotropins (FSH;LH)
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MenopurPowder, for solution75 unitSubcutaneousFerring Pharmaceuticals2006-09-19Not applicableCanada
MenopurKitFerring Pharmaceuticals2004-10-29Not applicableUs
RepronexPowder, for solution75 unitIntramuscular; SubcutaneousFerring Pharmaceuticals2003-08-28Not applicableCanada
Categories
UNII
5Y9QQM372Q
CAS number
9002-68-0

Pharmacology

Indication

For the treatment of female infertility

Structured Indications
Not Available
Pharmacodynamics

Used to treat female infertility, Menotropins stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Menotropins bind to the LH/hCG/FSH receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.

Mechanism of action

Being a combination drug, Menotropins bind to the follicle stimulating hormone receptor (FSH), which results in ovulation in the absence of sufficient endogenous luteinizing hormone (LH). It also binds the LH receptor, thereby stimulating proper hormone release. The drug contains both FSH and LH, therefore, it induces ovarian follicular growth and development as well as gonadal steroid production in women who do not have ovarian failure. FSH is the primary driver of follicular recruitment and growth in early folliculogenesis, while LH is important for ovarian steroidogenesis and is involved in the physiological events leading to development of a competent pre-ovulatory follicle.

TargetActionsOrganism
AFollicle-stimulating hormone receptor
binder
Human
ALutropin-choriogonadotropic hormone receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
No interactions found.
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
UniProt
P01229
Genbank
X00264
ChEMBL
CHEMBL2108427
Therapeutic Targets Database
DAP001027
PharmGKB
PA164749406
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Menotropins
ATC Codes
G03GA02 — Human menopausal gonadotrophin
AHFS Codes
  • 68:18.00
PDB Entries
FDA label
Download (175 KB)
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedScreeningInfertilities1
3CompletedTreatmentInfertilities2
3CompletedTreatmentSubfertility1
4CompletedTreatmentAnovulatory cycle / Infertilities1
4CompletedTreatmentFertility / Optimal Stimulation Protocol / Reproductive Endocrinology1
4CompletedTreatmentInfertilities7
4CompletedTreatmentInfertilities / Polycystic Ovarian Syndrome1
4CompletedTreatmentOvarian Stimulation Preceding Intrauterine Insemination1
4CompletedTreatmentPolycystic Ovaries Syndrome1
4Not Yet RecruitingTreatmentInfertility, Female1
4RecruitingTreatmentEgg Donation1
4RecruitingTreatmentInfertility, Female1
4Unknown StatusTreatmentFemale Reproductive Problem / Infertilities1
4Unknown StatusTreatmentInfertilities1
Not AvailableActive Not RecruitingNot AvailableInfertilities1
Not AvailableCompletedOtherInfertilities1
Not AvailableCompletedTreatmentFertility1
Not AvailableCompletedTreatmentIdiopathic Hypogonadotropic Hypogonadism1
Not AvailableCompletedTreatmentSubfertility1
Not AvailableEnrolling by InvitationScreeningInfertility, Female / Single Nucleotide Polymorphism,GnRH Receptor, IVF1
Not AvailableEnrolling by InvitationTreatmentInfertilities1
Not AvailableNot Yet RecruitingOtherEmbryonic Quality Using MitoScore (DuoStim x Conventional Stimulation Protocol) / Potential Usefulness of the DuoStim Protocol / Rate of Euploid Embryos Per Cycle (DuoStim x Conventional Stimulation Protocol)1
Not AvailableRecruitingNot AvailableInfertilities2
Not AvailableRecruitingTreatmentFertility / Infertilities1
Not AvailableUnknown StatusTreatmentInfertilities1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Kit
Powder, for solutionSubcutaneous75 unit
Powder, for solutionIntramuscular; Subcutaneous75 unit
Prices
Unit descriptionCostUnit
Repronex 5 75 unit Solution 1 Box Contains Five 1ml Vials488.04USD box
Menopur 75 unit vial93.85USD vial
Repronex 75 unit vial93.85USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)55 °CForastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)
hydrophobicity-0.063Not Available
isoelectric point8.44Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
G-protein coupled peptide receptor activity
Specific Function
Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Induces cAMP production through the activation of PI3K-AKT and S...
Gene Name
FSHR
Uniprot ID
P23945
Uniprot Name
Follicle-stimulating hormone receptor
Molecular Weight
78264.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW: Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online. 2003 Nov;7(5):547-57. [PubMed:14680547]
  4. Olive DL: The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65. [PubMed:7872378]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Luteinizing hormone receptor activity
Specific Function
Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.
Gene Name
LHCGR
Uniprot ID
P22888
Uniprot Name
Lutropin-choriogonadotropic hormone receptor
Molecular Weight
78642.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW: Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online. 2003 Nov;7(5):547-57. [PubMed:14680547]
  4. Olive DL: The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65. [PubMed:7872378]

Drug created on June 13, 2005 07:24 / Updated on June 26, 2017 15:59